Abstract
Background: We evaluated breast cancer (BC) core biopsies taken before neoadjuvant chemotherapy (NACT) by immunohistochemistry using anti-phosphohistone H3 (PHH3) antibody to determine mitosis, and correlated the results to clinicopathological data and histopathological regression of resected tumor specimens after NACT. Methods: 72 patients with either triple-negative (TN) or luminal type BC received NACT with epirubicin/cyclo-phosphamide (EC) and Taxotere((R)). Tumor regression was analyzed in resected specimens; pathological complete response (pCR) was achieved in 22.2%. Immunohistochemistry with PHH3 was performed on biopsy samples taken before treatment, and mitotic figures were evaluated in 10 high-power fields (HPF). Results: PHH3-detected mitoses correlated significantly with tumor grading (p = 0.001). TNBC showed > 10 PHH3-positive mitoses/10 HPF significantly more frequently than luminal type BC (p = 0.003). Tumors with > 10 PHH3-positive mitoses/10 HPF achieved pCR significantly more often than those with <10 PHH3-positive mitoses/10 HPF (p = 0.031). Even luminal type BC with > 10 PHH3-positive mitoses/10 HPF was associated significantly with pCR compared to luminal type BC with 10 PHH3-positive mitoses/10 HPF). Immunohistochemical determination of mitoses using anti-PHH3 antibody is a simple and robust method for predicting therapy response to NACT in BC tissue. (C) 2017 S. Karger GmbH, Freiburg
Original language | English |
---|---|
Pages (from-to) | 244-250 |
Number of pages | 7 |
Journal | Breast Care |
Volume | 12 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2017 |
Keywords
- Breast cancer
- Mitotic count
- PHH3
- Neoadjuvant therapy
- SURGICAL ADJUVANT BREAST
- PREOPERATIVE CHEMOTHERAPY
- PROGNOSTIC VALUE
- PROLIFERATION
- CARCINOMA
- PHOSPHORYLATION
- RECOMMENDATIONS
- CONDENSATION
- EXPRESSION
- CONSENSUS